- It is expected that the AmboVent machine will cost less than $1,000 when mass-produced
- At the moment the project team is working in collaboration with over 100 development teams across 30 countries
Israeli nonprofit AmboVent that developed a resuscitator device powered by a robotic arm and sophisticated computer system has announced a crowdfunding campaign to allow its invention to be built anytime and anywhere. It said that the device was developed in 10days by a team of entrepreneurs and organizations led by Dr. David Alkahar and Dr. Eitan Eliram, as part of the global Coronavirus pandemic response.
Dr. Eitan Eliram, AmboVent director of global partnerships said, “Our goal is to support the development and local mass production capabilities of ventilators in many countries. We are excited to offer our open-source design and technical support to all people, countries, and governments. This is a time for humanity to come together.”
Cost less than $1,000 when mass-produced
The project was shared via Github. This makes it accessible to developers and engineers globally. It is expected that the AmboVent machine will cost less than $1,000 when mass-produced. AmboVent said that the invention was made possible in part by support from tech companies such as Lemonade (AI-powered insurance company) whose team members helped to get it off the ground. At the moment the project team is working in collaboration with over 100 development teams across 30 countries.
AmboVent has launched a joint crowdfunding campaign to raise funds. This will enable it to provide the device to patients in countries where other breathing support devices are not currently available.
Daniel Schreiber, Lemonade CEO and co-founder said, “The shortage and expense of life-saving ventilators have been a major concern since the pandemic began, and is an especially acute worry as Covid-19 accelerates in the developing world. As an open-source, technology-driven effort to save lives, AmboVent was one of the initiatives our team was keen to help out with.”